Nuo Therapeutics, Inc. (AURX) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
AURX steht fuer Nuo Therapeutics, Inc., ein Healthcare-Unternehmen mit einem Kurs von $ (Marktkapitalisierung 0). Die Aktie erzielt 61/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.
Zuletzt analysiert: 17. März 2026Nuo Therapeutics, Inc. (AURX) Gesundheitswesen & Pipeline-Uebersicht
Nuo Therapeutics, Inc. operates in the regenerative medicine sector, focusing on cell-based therapies for chronic wound care. The company's core technology leverages autologous blood to produce platelet-based treatments, addressing a critical need in accelerating natural healing processes within the United States.
Investmentthese
Nuo Therapeutics, Inc. presents a high-risk, high-reward investment profile within the regenerative medicine sector. The company's focus on platelet-based therapies for chronic wound care addresses a significant market need. However, with a market capitalization of $0.07 billion and a negative P/E ratio of -27.22, the company's financial stability is a concern. A gross margin of 70.4% indicates strong potential profitability if sales can be scaled. Key growth catalysts include successful clinical trials and strategic partnerships to expand market access. The primary risk lies in the company's ability to secure funding and navigate the regulatory landscape for its cell-based therapies.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market capitalization of $0.07 billion reflects its small size and potential for high volatility.
- Negative P/E ratio of -27.22 indicates the company is currently unprofitable.
- Gross margin of 70.4% suggests strong potential profitability if sales volume increases.
- Beta of -104.09 indicates an inverse correlation with the market, which is unusual and may be due to the stock's illiquidity.
- The company focuses on regenerative therapies, a growing area within healthcare.
Wettbewerber & Vergleichsunternehmen
Staerken
- Proprietary technology in platelet-based therapies.
- Focus on regenerative medicine, a growing field.
- Potential for personalized treatments using autologous blood.
- Established presence in the chronic wound care market.
Schwaechen
- Small market capitalization and limited financial resources.
- Negative P/E ratio indicating current unprofitability.
- Reliance on a single technology platform.
- Limited geographic reach.
Katalysatoren
- Upcoming: Potential for positive clinical trial results for its platelet-based therapy.
- Ongoing: Strategic partnerships to expand market access and distribution.
- Ongoing: Development of new applications for its core technology in regenerative medicine.
Risiken
- Potential: Regulatory hurdles for cell-based therapies.
- Potential: Competition from larger companies with more resources.
- Ongoing: Limited financial resources and potential need for additional funding.
- Ongoing: Risk of clinical trial failures or delays.
- Potential: Dependence on a single technology platform.
Wachstumschancen
- Expansion into new therapeutic areas: Nuo Therapeutics can leverage its core technology to develop therapies for other regenerative medicine applications, such as orthopedic injuries or cosmetic surgery. The market for regenerative medicine is projected to reach $124 billion by 2030, presenting a significant growth opportunity. Timeline: 3-5 years.
- Strategic partnerships: Collaborating with larger pharmaceutical or medical device companies can provide Nuo Therapeutics with access to broader distribution networks and increased funding for research and development. This could accelerate the commercialization of its products and expand its market reach. Timeline: 1-2 years.
- Geographic expansion: While currently focused on the United States, Nuo Therapeutics can explore opportunities to expand its market presence into other countries with large and growing wound care markets, such as Europe and Asia. This would require navigating different regulatory environments and establishing local partnerships. Timeline: 3-5 years.
- Development of next-generation products: Investing in research and development to improve the efficacy and ease of use of its platelet-based therapy can provide Nuo Therapeutics with a competitive advantage. This could involve developing new formulations or delivery methods. Timeline: 2-3 years.
- Acquisition of complementary technologies: Acquiring other companies with complementary technologies in the regenerative medicine space can broaden Nuo Therapeutics' product portfolio and create synergies. This could involve acquiring companies with expertise in cell therapy, gene therapy, or tissue engineering. Timeline: 2-3 years.
Chancen
- Expansion into new therapeutic areas.
- Strategic partnerships with larger companies.
- Geographic expansion into international markets.
- Development of next-generation products.
Risiken
- Competition from larger companies with more resources.
- Regulatory hurdles for cell-based therapies.
- Risk of clinical trial failures.
- Potential for technological obsolescence.
Wettbewerbsvorteile
- Proprietary technology for platelet-based therapies.
- Focus on autologous blood, potentially reducing risk of rejection.
- Established presence in the chronic wound care market.
- Potential for strong relationships with healthcare providers.
Ueber AURX
Nuo Therapeutics, Inc., formerly known as Cytomedix, Inc., was established in 1998 and rebranded in November 2014 to reflect its focus on regenerative therapies. Headquartered in Houston, Texas, the company develops, commercializes, and markets cell-based technologies designed to harness the body's natural healing capabilities. Their primary product is a platelet-based therapy derived from autologous blood, targeting the chronic wound care market. This technology involves separating a patient's own blood to create a treatment that stimulates natural healing processes. Nuo Therapeutics aims to address the significant unmet needs in chronic wound management, offering innovative solutions to improve patient outcomes and reduce healthcare costs associated with non-healing wounds. The company's strategic focus is on expanding the application of its core technology and establishing partnerships to broaden its market reach within the United States.
Was das Unternehmen tut
- Develops cell-based technologies for regenerative medicine.
- Commercializes therapies that harness the body's natural healing processes.
- Markets platelet-based treatments for chronic wound care.
- Utilizes autologous blood to create personalized therapies.
- Focuses on addressing unmet needs in chronic wound management.
- Aims to improve patient outcomes and reduce healthcare costs.
Geschaeftsmodell
- Develops and manufactures platelet-based therapies.
- Markets and sells these therapies to healthcare providers.
- Generates revenue through product sales.
- Potentially licenses its technology to other companies.
Branchenkontext
Nuo Therapeutics operates within the regenerative medicine sector, a rapidly growing field focused on developing therapies that repair or replace damaged tissues and organs. The market for wound care is substantial, driven by an aging population and increasing prevalence of chronic diseases such as diabetes. Competition includes companies developing advanced wound dressings, biologics, and cell-based therapies. Nuo Therapeutics aims to differentiate itself through its autologous platelet-based technology, offering a potentially more effective and personalized approach to wound healing.
Wichtige Kunden
- Hospitals and wound care centers.
- Physicians specializing in wound management.
- Patients with chronic wounds.
- Potentially, long-term care facilities.
Finanzdaten
Chart & Info
Nuo Therapeutics, Inc. (AURX) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer AURX verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer AURX.
Kursziele
Wall-Street-Kurszielanalyse fuer AURX.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von AURX auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: David E. Jorden
CEO
David E. Jorden serves as the CEO of Nuo Therapeutics, Inc. His background includes experience in managing and leading small teams, as evidenced by his current role overseeing nine employees. Information regarding his specific educational background and previous roles is not available from the provided source data. His expertise appears to be centered on the operational and strategic management of companies within the healthcare sector, particularly those focused on regenerative therapies.
Erfolgsbilanz: Due to the limited information available, it is difficult to assess David E. Jorden's specific track record at Nuo Therapeutics. However, as CEO, he is responsible for guiding the company's strategic direction, overseeing the development and commercialization of its cell-based therapies, and managing its financial performance. The company's focus on regenerative medicine and its platelet-based therapy for chronic wound care are key initiatives under his leadership.
AURX OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that Nuo Therapeutics may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies are not subject to the same stringent listing standards, which increases the risk of investing in these securities.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure increases the risk of investing in AURX.
- Low trading volume and liquidity can lead to price volatility.
- The company may not meet the minimum financial standards of higher OTC tiers.
- OTC Other companies are subject to less regulatory oversight than exchange-listed companies.
- Potential for fraud or manipulation is higher in the OTC market.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and regulatory approvals.
- Determine the company's capital structure and debt levels.
- Monitor the company's news and press releases for any red flags.
- Consult with a financial advisor before investing.
- The company has been in operation since 1998.
- Focus on regenerative medicine, a legitimate and growing field.
- Development of platelet-based therapies for chronic wound care.
- Presence in the chronic wound care market.
Haeufige Fragen zu AURX
What are the key factors to evaluate for AURX?
Nuo Therapeutics, Inc. (AURX) currently holds an AI score of 61/100, indicating moderate score. Key strength: Proprietary technology in platelet-based therapies.. Primary risk to monitor: Potential: Regulatory hurdles for cell-based therapies.. This is not financial advice.
How frequently does AURX data refresh on this page?
AURX prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven AURX's recent stock price performance?
Recent price movement in Nuo Therapeutics, Inc. (AURX) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary technology in platelet-based therapies.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider AURX overvalued or undervalued right now?
Determining whether Nuo Therapeutics, Inc. (AURX) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying AURX?
Before investing in Nuo Therapeutics, Inc. (AURX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding AURX to a portfolio?
Potential reasons to consider Nuo Therapeutics, Inc. (AURX) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Proprietary technology in platelet-based therapies.. Additionally: Focus on regenerative medicine, a growing field.. The AI-driven MoonshotScore of 61/100 reflects solid quantitative fundamentals. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of AURX?
Yes, most major brokerages offer fractional shares of Nuo Therapeutics, Inc. (AURX) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track AURX's earnings and financial reports?
Nuo Therapeutics, Inc. (AURX) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for AURX earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Limited information available on CEO's track record.
- Disclosure status on OTC market is unknown.